Differences in Anti-αvβ6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf246 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Yoichi Kakuta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Colitis, Ulcerative, Crohn Disease, Integrins. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, KAKENHI, Tohoku University.
Abstract (Originalsprache)
Background
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), have complex pathologies requiring precise diagnostic tools. We evaluated the clinical utility of anti-integrin αvβ6 antibodies in diagnosing UC, focusing on differences between a U.S. cohort (self-reported White) and a Japanese cohort, and additionally assessed whether combining anti-αvβ6 with anti-EPCR improved diagnostic performance.
Methods
Serum anti-αvβ6 antibody levels were measured in 1138 participants (514 in the U.S. cohort, 624 in the Japanese cohort), including 1093 IBD cases and 45 healthy control subjects. Positivity rates and titers were compared between cohorts, and associations with clinical subphenotypes and anti-EPCR were examined.
Results
Anti-αvβ6 positivity was significantly higher in UC patients (85.4%) than in CD patients (16.4%) or control subjects (0%). Within UC, high positivity was observed across all disease extents, with only minor cohort differences. Longer disease duration was associated with lower positivity in both cohorts. In CD, the U.S. cohort showed higher positivity (23.4%) than the Japanese cohort (10.1%), particularly in colonic CD. Absence of ileal involvement, strictures, or perianal disease was associated with higher positivity. Anti-αvβ6 and anti-EPCR levels were strongly correlated, but their expression patterns differed in primary sclerosing cholangitis–associated IBD. Combining anti-αvβ6 and anti-EPCR improved UC diagnostic accuracy (area under the curve, 0.98; 95% confidence interval, 0.95-1.00) over either antibody alone (P = .00264).
Conclusions
Anti-αvβ6 is a valuable biomarker for UC diagnosis. However, this study demonstrated differences in its behavior between U.S. and Japanese cohorts, particularly in CD. Cohort-informed interpretation and combined antibody testing may improve diagnostic precision and disease stratification in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
- F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, United States.
- Department of Rheumatology, Tohoku University Hospital, Sendai, 980-8574, Japan.
- Student Healthcare Center, Institute for Excellence in Higher Education, Tohoku University, Sendai, 980-8576, Japan.
ORCID-Profile: Yoichi Kakuta, Tsuyoshi Shirai, Hiroshi Fujii
Förderung
- Japan Society for the Promotion of Science
- KAKENHI
- Tohoku University
- Medical & Biological Laboratories Co., Ltd.
- Labor Sciences Research Grants for Research
- Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan
- F. Widjaja Inflammatory Bowel Disease Institute of Cedars-Sinai Medical Center
Zitieren
APA
Kakuta, Y., Li, D., Debbas, P., Okazaki, S., Sawahashi, M., Yang, S., Iwaki, H., Okamoto, D., Nagai, H., Shimoyama, Y., Naito, T., Moroi, R., Kuroha, M., Shiga, H., Kinouchi, Y., Shirai, T., Fujii, H., McGovern, D. P. B., & Masamune, A. (2026). Differences in Anti-αvβ6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf246
Vancouver
Kakuta Y, Li D, Debbas P, Okazaki S, Sawahashi M, Yang S, et al. Differences in Anti-αvβ6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf246
BibTeX
@article{Kakuta2026,
author = {Kakuta, Yoichi and Li, Dalin and Debbas, Philip and Okazaki, Soshi and Sawahashi, Motoi and Yang, Shaohong and Iwaki, Hideya and Okamoto, Daisuke and Nagai, Hiroshi and Shimoyama, Yusuke and Naito, Takeo and Moroi, Rintaro and Kuroha, Masatake and Shiga, Hisashi and Kinouchi, Yoshitaka and Shirai, Tsuyoshi and Fujii, Hiroshi and McGovern, Dermot P B and Masamune, Atsushi},
title = {Differences in Anti-αvβ6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf246}
}
EUVIMED